Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16188227rdf:typepubmed:Citationlld:pubmed
pubmed-article:16188227lifeskim:mentionsumls-concept:C0521329lld:lifeskim
pubmed-article:16188227lifeskim:mentionsumls-concept:C0012472lld:lifeskim
pubmed-article:16188227lifeskim:mentionsumls-concept:C0389995lld:lifeskim
pubmed-article:16188227lifeskim:mentionsumls-concept:C1419063lld:lifeskim
pubmed-article:16188227lifeskim:mentionsumls-concept:C1157570lld:lifeskim
pubmed-article:16188227lifeskim:mentionsumls-concept:C0086597lld:lifeskim
pubmed-article:16188227lifeskim:mentionsumls-concept:C0449560lld:lifeskim
pubmed-article:16188227pubmed:issue1lld:pubmed
pubmed-article:16188227pubmed:dateCreated2005-11-2lld:pubmed
pubmed-article:16188227pubmed:abstractTextProstaglandin E2 (PGE2), the principal pro-inflammatory prostanoid, is known to play versatile roles in pain transmission via four PGE receptor subtypes, EP1-EP4. We recently demonstrated that continuous production of nitric oxide (NO) by neuronal NO synthase (nNOS) following phosphorylation of myristoylated alanine-rich C-kinase substrate (MARCKS) and NMDA receptor NR2B subunits is essential for neuropathic pain. These phosphorylation and nNOS activity visualized by NADPH-diaphorase histochemistry were blocked by indomethacin, a PG synthesis inhibitor. To clarify the interaction between cyclooxygenase and nNOS pathways in the spinal cord, we examined the effect of EP subtype-selective agonists on NO production. NO formation was stimulated in the spinal superficial layer by EP1, EP3, and EP4 agonists. While the EP1- and the EP4-stimulated NO formation was markedly blocked by MK-801, an NMDA receptor antagonist, the EP3-stimulated one was completely inhibited by H-1152, a Rho-kinase inhibitor. Phosphorylation of MARCKS and NADPH-diaphorase activity stimulated by the EP3 agonist were also blocked by H-1152. These results suggest that PGE2 stimulates NO formation by Rho-kinase via EP3, a mechanism(s) different from EP1 and EP4.lld:pubmed
pubmed-article:16188227pubmed:languageenglld:pubmed
pubmed-article:16188227pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16188227pubmed:citationSubsetIMlld:pubmed
pubmed-article:16188227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16188227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16188227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16188227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16188227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16188227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16188227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16188227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16188227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16188227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16188227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16188227pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16188227pubmed:statusMEDLINElld:pubmed
pubmed-article:16188227pubmed:monthDeclld:pubmed
pubmed-article:16188227pubmed:issn0006-291Xlld:pubmed
pubmed-article:16188227pubmed:authorpubmed-author:SuzukiMasaaki...lld:pubmed
pubmed-article:16188227pubmed:authorpubmed-author:ItoSeijiSlld:pubmed
pubmed-article:16188227pubmed:authorpubmed-author:AbeTetsuyaTlld:pubmed
pubmed-article:16188227pubmed:authorpubmed-author:MinamiToshiak...lld:pubmed
pubmed-article:16188227pubmed:authorpubmed-author:MabuchiTamaki...lld:pubmed
pubmed-article:16188227pubmed:authorpubmed-author:HidakaHiroyos...lld:pubmed
pubmed-article:16188227pubmed:authorpubmed-author:SasakiYasuhar...lld:pubmed
pubmed-article:16188227pubmed:authorpubmed-author:MatsumuraShin...lld:pubmed
pubmed-article:16188227pubmed:authorpubmed-author:Okuda-Ashitak...lld:pubmed
pubmed-article:16188227pubmed:authorpubmed-author:NakaiYoshihid...lld:pubmed
pubmed-article:16188227pubmed:authorpubmed-author:TatsumiShinic...lld:pubmed
pubmed-article:16188227pubmed:authorpubmed-author:TakagiKunioKlld:pubmed
pubmed-article:16188227pubmed:authorpubmed-author:KatanoTayoTlld:pubmed
pubmed-article:16188227pubmed:issnTypePrintlld:pubmed
pubmed-article:16188227pubmed:day9lld:pubmed
pubmed-article:16188227pubmed:volume338lld:pubmed
pubmed-article:16188227pubmed:ownerNLMlld:pubmed
pubmed-article:16188227pubmed:authorsCompleteYlld:pubmed
pubmed-article:16188227pubmed:pagination550-7lld:pubmed
pubmed-article:16188227pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:meshHeadingpubmed-meshheading:16188227...lld:pubmed
pubmed-article:16188227pubmed:year2005lld:pubmed
pubmed-article:16188227pubmed:articleTitleRho-kinase mediates spinal nitric oxide formation by prostaglandin E2 via EP3 subtype.lld:pubmed
pubmed-article:16188227pubmed:affiliationDepartment of Medical Chemistry, Kansai Medical University, Moriguchi 570-8506, Japan.lld:pubmed
pubmed-article:16188227pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16188227pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16188227lld:pubmed